The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


Will PARTNER change my practice? Placement of Aortic Transcatheter Valves (PARTNER) 2 Cohort A trial – transcatheter or surgical aortic-valve replacement in intermediate-risk patients

EuroIntervention 2016;12:805-808. DOI: 10.4244/EIJV12I6A131

1. St. Thomas’ Hospital, London, United Kingdom; 2. Cedars-Sinai Heart Institute, Los Angeles, CA, USA; 3. King’s College Hospital, London, United Kingdom; 4. Charles Nicolle Hospital, Rouen, France; 5. Rigshospitalet, Copenhagen, Denmark

Introduction to the session

The aim of the article is to capture the session at EuroPCR 2016, communicate the analysis of the trialist, and report the views expressed in the interactive discussion. The article does not constitute an independent review of the topic by the authors. The session focused on whether the PARTNER 2 Cohort A trial will change clinical practice1.


The introductory comments highlighted that the indications for TAVI in 2016 are “frozen in time”, being based upon ESC and ACC/AHA guidelines published in 2012 and 2014, respectively. The pivotal PARTNER 1 trial demonstrated the utility of TAVI in ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Will SPRINT change my practice? SPRINT: a randomised trial of intensive versus standard blood-pressure control